MA43556A - Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci - Google Patents

Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci

Info

Publication number
MA43556A
MA43556A MA043556A MA43556A MA43556A MA 43556 A MA43556 A MA 43556A MA 043556 A MA043556 A MA 043556A MA 43556 A MA43556 A MA 43556A MA 43556 A MA43556 A MA 43556A
Authority
MA
Morocco
Prior art keywords
antibody
combinations
tlr4 modulator
tlr4
modulator
Prior art date
Application number
MA043556A
Other languages
English (en)
Inventor
Christopher John Francis
Hua-Xin Gao
Yufeng Li
Niranjan Yanamandra
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA43556A publication Critical patent/MA43556A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA043556A 2015-08-06 2016-06-03 Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci MA43556A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562201828P 2015-08-06 2015-08-06
US201562247488P 2015-10-28 2015-10-28
US201662300400P 2016-02-26 2016-02-26
US201662322906P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
MA43556A true MA43556A (fr) 2021-03-24

Family

ID=56131579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043556A MA43556A (fr) 2015-08-06 2016-06-03 Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci

Country Status (21)

Country Link
US (2) US20170275371A1 (fr)
EP (1) EP3331560A1 (fr)
JP (2) JP2018525378A (fr)
KR (1) KR20180032641A (fr)
CN (1) CN108025073A (fr)
AU (1) AU2016304401B2 (fr)
BR (1) BR112018002530A2 (fr)
CA (1) CA2994910A1 (fr)
CL (1) CL2018000303A1 (fr)
CO (1) CO2018001238A2 (fr)
CR (1) CR20180080A (fr)
DO (1) DOP2018000034A (fr)
EA (1) EA201890457A1 (fr)
HK (1) HK1249410A1 (fr)
IL (1) IL257067A (fr)
MA (1) MA43556A (fr)
MX (1) MX2018001515A (fr)
PH (1) PH12018500254A1 (fr)
TW (1) TW201716084A (fr)
WO (1) WO2017021791A1 (fr)
ZA (1) ZA201800468B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2019133647A1 (fr) * 2017-12-29 2019-07-04 Thevax Genetics Vaccine Co., Ltd. Combinaison d'un vaccin à protéine de fusion avec un anticorps anti-ox40 destinée à être utilisée pour déclencher des réponses immunitaires spécifiques de l'antigène
WO2020030570A1 (fr) * 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps ox40 et d'un modulateur de tlr4 et leurs utilisations
EP3937984A1 (fr) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
CN113891747A (zh) * 2019-05-15 2022-01-04 郑州威瑞生物技术有限公司 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
TW202233200A (zh) * 2020-11-11 2022-09-01 日商第一三共股份有限公司 新穎胺基烷基葡萄胺糖苷4-磷酸衍生物
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
PT1284740E (pt) 2000-05-19 2008-07-09 Corixa Corp Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
CA2417806C (fr) 2000-08-04 2011-05-10 Corixa Corporation Nouveaux composes immuno-effecteurs
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
US7387271B2 (en) * 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
US7960522B2 (en) * 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2543360A1 (fr) 2003-10-24 2005-05-06 Joost A. Kolkman Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
LT2609118T (lt) * 2010-08-23 2017-04-25 Board Of Regents, The University Of Texas System Anti-ox40 antikūnai ir jų panaudojimo būdai
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
JP6038920B2 (ja) * 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
EP2659906A1 (fr) * 2012-05-01 2013-11-06 Affiris AG Compositions
MX2016007965A (es) * 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.

Also Published As

Publication number Publication date
KR20180032641A (ko) 2018-03-30
US20190338042A1 (en) 2019-11-07
BR112018002530A2 (pt) 2018-09-25
CN108025073A (zh) 2018-05-11
CL2018000303A1 (es) 2018-07-06
MX2018001515A (es) 2018-03-15
US20170275371A1 (en) 2017-09-28
ZA201800468B (en) 2019-07-31
TW201716084A (zh) 2017-05-16
AU2016304401A1 (en) 2018-02-15
HK1249410A1 (zh) 2018-11-02
WO2017021791A1 (fr) 2017-02-09
IL257067A (en) 2018-03-29
CA2994910A1 (fr) 2017-02-09
JP2018525378A (ja) 2018-09-06
CO2018001238A2 (es) 2018-05-10
JP2021121622A (ja) 2021-08-26
PH12018500254A1 (en) 2018-08-13
EA201890457A1 (ru) 2018-09-28
CR20180080A (es) 2018-04-02
AU2016304401B2 (en) 2019-05-16
EP3331560A1 (fr) 2018-06-13
DOP2018000034A (es) 2018-10-31

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
EP3356416A4 (fr) Anticorps anti-pd-1 et ses utilisations
EP3638320A4 (fr) Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
EP3400243A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3684812A4 (fr) Anticorps anti-ctla4 et utilisations associées
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3838289A4 (fr) Anticorps anti-tigit et ses utilisations
EP3377102A4 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
MA46525A (fr) Anticorps anti-lag-3 et compositions
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA44659A (fr) Anticorps anti-tim-3 et compositions
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3370770A4 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
EP3735427A4 (fr) Anticorps anti-mct1 et utilisations associées
EP3733702A4 (fr) Anticorps anti-lag-3 et utilisations associées
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations